Vericel (VCEL) Non-Current Deffered Revenue (2016 - 2019)
Vericel's (VCEL) quarterly Non-Current Deffered Revenue came in at $134000.0 in Q2 2019, down 92.95% year-on-year from $1.9 million in Q2 2018, and down 92.95% quarter-over-quarter from $1.9 million in Q1 2019.
Vericel (VCEL) Non-Current Deffered Revenue (2016 - 2019) Analysis & Trends
Vericel has disclosed Non-Current Deffered Revenue across 4 years of filings, most recently posting $134000.0 for Q2 2019.
- Non-Current Deffered Revenue for Q2 2019 came in at $134000.0, down 92.95% year-over-year; the trailing twelve-month figure through Jun 2019 was $134000.0 (down 92.95% YoY), and the FY2018 annual result was $1.7 million, down 19.09% from the prior year.
- Non-Current Deffered Revenue came in at $134000.0 for Q2 2019 at Vericel, down from $1.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $2.1 million in Q4 2017 to a low of $134000.0 in Q2 2019.
- The 4-year median for Non-Current Deffered Revenue is $1.7 million (2018), against an average of $1.5 million.
- Across the five-year window, Non-Current Deffered Revenue jumped 111.11% in 2018 and tumbled 92.95% in 2019, its largest moves.
- Vericel's Non-Current Deffered Revenue stood at $1.7 million in 2016, then gained by 22.05% to $2.1 million in 2017, then declined by 19.09% to $1.7 million in 2018, then plunged by 91.96% to $134000.0 in 2019.
- The last three Non-Current Deffered Revenue figures came in at $134000.0 (Q2 2019), $1.9 million (Q1 2019), and $1.7 million (Q4 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 134,000.00 |
| Mar 31, 2019 | 1.90 Mn |
| Dec 31, 2018 | 1.67 Mn |
| Sep 30, 2018 | 1.81 Mn |
| Jun 30, 2018 | 1.90 Mn |
| Mar 31, 2018 | 1.95 Mn |
| Dec 31, 2017 | 2.06 Mn |
| Sep 30, 2017 | 1.61 Mn |
| Jun 30, 2017 | 900,000.00 |
| Mar 31, 2017 | 1.63 Mn |
| Dec 31, 2016 | 1.69 Mn |
| Sep 30, 2016 | 900,000.00 |
| Jun 30, 2016 | 900,000.00 |